Menactra (Sanofi Pasteur) indication is expanded by FDA

Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group announced that the FDA has granted a license to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through 23 months of age. This is the first U.S. approval of a meningococcal vaccine for this age group.